Heres what the clinical evidence shows: Study Scope: 900+ participants across 6 randomized, double-blind, placebo-controlled trials Safety Profile: Indistinguishable from placebo in tolerability assessments Serious Events: Zero serious adverse events attributed to AOD-9604 Withdrawals: No treatment-related discontinuations in any trial Common Effects: Mild headache and minor GI symptoms at rates similar to placebo IGF-1 Impact: No effect on insulin-like growth factor-1 levels Metabolic Safety: No negative impact on glucose metabolism or insulin sensitivity Immunogenicity: Zero participants developed anti-AOD9604 antibodies The following analysis provides complete details on the clinical trial evidence supporting AOD-9604s favorable safety profile
A: These tablets are intended for adult men and women seeking dietary support for skin care and general well-being
It can flip the switch on thousands of genes, encouraging older cells to act more like their younger counterparts
5 Future directions The clinical load of neurodegenerative diseases like AD and PD is projected to increase exponentially in coming years, with a commensurate increase in need for potential treatments
IGF-1R is crucial for tumour transformation and survival of malignant cell, but is only partially involved in normal cell growth
Read review Dihexa for Sleep Apnea Brain Fog OSA & hypoxemia, REM CA1 hippocampal loss (UC Irvine May 2025), Zepbound (tirzepatide) FDA approval Dec 2024 (SURMOUNT-OSA), NICE NG202, and the ~13 million UK adults estimated to have OSA